The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review is a research paper published in Blood and Lymphatic Cancer Targets and Therapy (2024). On theSindex it has a DataRank of 0. It has been cited 6 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R01 CA254961
FWCI
1.84
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals